Full Press Release Details
BOSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that it will report fourth quarter 2025 financial results on March 5, 2026, before the open of the U.S. financial markets. The company does not intend to hold a conference call.
Additionally, Tango Therapeutics management is scheduled to participate in three upcoming investor conferences:
TD Cowen 46thAnnual Health Care Conference, Boston
Barclays 28thAnnual Global Healthcare Conference, Miami
2026 Leerink Partners Global Healthcare Conference, Miami
The live webcast for each event will be available under the "Events & Presentations" tab on the “Investors” page of the Company's website on the day of the event. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.
About Tango TherapeuticsTango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more information, please visit www.tangotx.com.